Confirmed histological diagnosis of metastatic non-small cell lung cancer (both squamous and non-squamous histology);
First-line treatment with immunotherapy (alone or in combination with chemotherapy) for metastatic disease by investigators' choice within the framework of good clinical practice and in agreement with current guidelines;
Will to participate by providing written informed consent;
Availability to administer oral supplements and immunotherapy with or without chemotherapy;
Eastern Cooperative Oncology Group Performance Status ≤ 2;
Life expectancy ≥ 6 months.
You may not be if
Age \< 18 years;
Inability to sign an informed consent;
Indication to or ongoing artificial nutrition support (totally compromised spontaneous food-intake) and incapacity or unavailability to consume oral nutritional supplements
Clareo Health | Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer
